BioNTech SE
(NASDAQ : BNTX)

( )
BNTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.00%204.730.0%$1981.02m
NVAXNovavax, Inc. 0.00%110.8278.2%$792.93m
BIIBBiogen, Inc. 0.00%239.301.8%$522.63m
AMGNAmgen, Inc. 0.00%235.361.4%$522.04m
BNTXBioNTech SE 0.00%196.000.0%$501.82m
GILDGilead Sciences, Inc. 0.00%71.771.0%$472.12m
ILMNIllumina, Inc. 0.00%405.143.3%$406.87m
REGNRegeneron Pharmaceuticals, Inc. 0.00%615.242.7%$388.21m
VRTXVertex Pharmaceuticals, Inc. 0.00%234.061.9%$331.63m
SNSSSunesis Pharmaceuticals, Inc. 0.00%3.170.7%$221.59m
EXASEXACT Sciences Corp. 0.00%78.4317.9%$151.61m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%148.508.2%$151.18m
ARNAArena Pharmaceuticals, Inc. 0.00%92.6513.7%$144.29m
INCYIncyte Corp. 0.00%74.882.4%$128.10m
BBIOBridgeBio Pharma, Inc. 0.00%12.750.0%$115.66m

Company Profile

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.